Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

90.80DKK
16 Feb 2018
Change (% chg)

kr.0.30 (+0.33%)
Prev Close
kr.90.50
Open
kr.91.00
Day's High
kr.92.50
Day's Low
kr.90.20
Volume
142,744
Avg. Vol
130,089
52-wk High
kr.141.00
52-wk Low
kr.78.50

Select another date:

Wed, Feb 7 2018

BRIEF-Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017

* REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017

BRIEF-Zealand: Clinical Evidence Support Potential For Glepaglutide

* ZEALAND HAS COMPLETED A PHARMACOKINETIC (PK) STUDY WITH GLEPAGLUTIDE THAT CONFIRMS POTENTIAL FOR ONCE-WEEKLY DOSING

BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism

* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018

BRIEF-Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics

* ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC.

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

New Zealand forestry a first test in nationalist party's protectionist agenda

WELLINGTON Some New Zealand forest owners are suspending replanting of trees and re-thinking investments as the country's third-largest export earner finds itself in the sights of maverick politician Winston Peters' protectionist agenda.

BRIEF-Zealand Pharma to cooperate with Torrey Pines Institute for Molecular Studies

* REG-ZEALAND PHARMA AND TORREY PINES INSTITUTE FOR MOLECULAR STUDIES ANNOUNCE RESEARCH COLLABORATION

Select another date: